Orthofix Medical (NASDAQ:OFIX) Major Shareholder Juniper Investment Company, Ll Purchases 14,803 Shares of Stock

Orthofix Medical Inc. (NASDAQ:OFIX) major shareholder Juniper Investment Company, Ll bought 14,803 shares of the stock in a transaction dated Wednesday, November 11th. The shares were purchased at an average price of $7.04 per share, for a total transaction of $104,213.12. Following the purchase, the insider owned 4,461,019 shares of the company’s stock, valued at $31,405,573.76. This trade represents a 0.33% increase in their position. The acquisition was disclosed in a filing with the SEC, which is accessible through the SEC website. Large shareholders that own 10% or more of a company’s shares are required to disclose their sales and purchases with the SEC.

Juniper Investment Company, Ll also recently made the following trade(s):

• On Monday, November 9th, Juniper Investment Company, Ll purchased 675,000 shares of Orthofix Medical stock. The shares were purchased at an average cost of $7.41 per share, with a total value of $5,001,750.00.

Orthofix Medical Stock Performance

OFIX traded down $0.24 during trading on Thursday, hitting $6.94. The stock had a trading volume of 560,217 shares, compared to its average volume of 375,534. The company has a 50 day moving average price of $9.16 and a 200-day moving average price of $10.89. The firm has a market cap of $282.69 million, a price-to-earnings ratio of -6.20 and a beta of 0.66. Orthofix Medical Inc. has a one year low of $6.52 and a one year high of $16.42. The company has a debt-to-equity ratio of 0.55, a current ratio of 3.11 and a quick ratio of 1.67.

Orthofix Medical (NASDAQ:OFIX) last issued its quarterly earnings data on Monday, November 9th. The medical device company reported ($0.15) EPS for the quarter, beating analysts’ consensus estimates of ($0.26) by $0.11. The firm had revenue of $207.86 million for the quarter, compared to analyst estimates of $210.52 million. Orthofix Medical had a negative return on equity of 10.32% and a negative net margin of 5.39%. As a group, research analysts predict that Orthofix Medical Inc. will post -1.29 EPS for the current year.

Wall Street Analysts Forecast Growth

Several equities analysts recently commented on the stock. Canaccord Genuity Group decreased their price target on shares of Orthofix Medical from $18.00 to $13.00 and set a “buy” rating on the stock in a research note on Monday, August 10th. Weiss Ratings lowered shares of Orthofix Medical from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Tuesday, November 3rd. Finally, TD Cowen reiterated a “hold” rating on shares of Orthofix Medical in a research note on Tuesday. Three investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Hold” and an average target price of $14.75.

Institutional Investors Weigh In On Orthofix Medical

Several institutional investors have recently made changes to their positions in OFIX. Engine Capital Management LP grew its position in Orthofix Medical by 3.2% during the first quarter. Engine Capital Management LP now owns 4,390,779 shares of the medical device company’s stock worth $50,362,000 after buying an additional 137,858 shares in the last quarter. BlackRock Inc. bought a new position in Orthofix Medical during the 2nd quarter worth $30,405,000. Paradigm Capital Management Inc. NY acquired a new position in Orthofix Medical in the 2nd quarter valued at $30,167,000. Bank of America Corp DE acquired a new position in Orthofix Medical in the 2nd quarter valued at $2,667,000. Finally, Russell Investments Group Ltd. lifted its position in shares of Orthofix Medical by 37.5% during the 3rd quarter. Russell Investments Group Ltd. now owns 274,157 shares of the medical device company’s stock valued at $2,580,000 after acquiring an additional 74,838 shares during the period. 89.76% of the stock is currently owned by institutional investors.

About Orthofix Medical

Orthofix Medical Inc. develops and markets medical technologies for spine and orthopedic care. Its products include spinal implants and biologics, bone growth stimulation systems, and solutions used in fracture treatment and limb reconstruction. The company serves hospitals, surgeons, and other health care providers through its Orthofix and SeaSpine businesses. Its offerings span surgical products as well as noninvasive and specialized orthopedic treatments. Orthofix and SeaSpine completed a merger in 2023, combining their spine and orthopedic product portfolios.